TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference
TFF Pharmaceuticals (NASDAQ: TFFP) announced that President and CEO Glenn Mattes will participate in a fireside chat at the 34th Annual Roth Conference held in Dana Point, California, from March 13 to 15, 2022. The chat is scheduled for March 14 at 10:30 AM PT (1:30 PM ET) and will be moderated by Jonathan Aschoff, Ph.D., from Roth Capital Partners. Management will also engage in one-on-one meetings during the event. TFF Pharmaceuticals is focused on innovative drug products utilizing its patented Thin Film Freezing technology, aimed at improving the solubility and absorption of poorly water-soluble drugs.
- None.
- None.
AUSTIN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in a fireside chat at the 34th Annual Roth Conference in Dana Point, California March 13 - 15, 2022. Company management will also be participating in one-on-one meetings throughout the conference.
34th Annual Roth Conference (in-person)
| Date: | Monday, March 14, 2022 | |
| Time: | 10:30 am PT (1:30 pm ET) | |
| Moderator: | Jonathan Aschoff, Ph.D., Managing Director, Sr Research Analyst, Roth Capital Partners | |
| Presenter: | Glenn Mattes, President and Chief Executive Officer | |
| Location: | Suite 2022, The Ritz Carlton, Laguna Niguel located in Dana Point, California | |
| Format: | Fireside chat |
To learn more and submit a registration request, visit https://ibn.fm/ROTH2022Registration.
About Roth Capital Partners
Roth Capital Partners, LLC (Roth) is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.
Headquartered in Newport Beach, California, Roth is privately held and owned by its employees and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.
About TFF Pharmaceuticals’ Thin Film Freezing Technology Platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by over 120 patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
SAFE HARBOR
This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the expectations for its collaboration and referral arrangement with Catalent, the benefits of the Company’s TFF platform and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not achieve the favorable results expected from its collaboration and referral agreement with Catalent, (ii) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of any of its dry powder product candidates, (iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (v) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (vi) those other risks disclosed in the section “Risk Factors” included in the Company’s 2020 Annual Report on Form 10-K filed with the SEC on March 10, 2021. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
TFF Pharmaceuticals Investor Relations Contact:
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
212-915-2577
TFF Pharmaceuticals Media Contact:
Gwendolyn Schanker
LifeSci Communications
(269) 921-3607
gschanker@lifescicomms.com
Source: TFF Pharmaceuticals, Inc.
FAQ
What is the date of TFF Pharmaceuticals' participation in the Roth Conference?
What time will the fireside chat with Glenn Mattes take place at the Roth Conference?
Who is moderating the fireside chat at the 34th Annual Roth Conference?
Where is the Roth Conference being held?
What technology does TFF Pharmaceuticals focus on?
What are the lead drug candidates of TFF Pharmaceuticals?
